Browsing Category
Health
Johnson & Johnson (JNJ) Q3 earnings report 2023
Johnson & Johnson on Tuesday reported adjusted earnings and revenue that topped Wall Street's expectations, and lifted its full-year guidance as sales in…
When is it OK to violate your value foundation to purchase extra shares of an organization?
Here's our Club Mailbag email investingclubmailbag@cnbc.com — so you send your questions directly to Jim Cramer and his team of analysts. We can't offer…
Ceremony Assist recordsdata for chapter amid slowing gross sales, opioid litigation
A Rite Aid store stands in Brooklyn on August 28, 2023 in New York City.Spencer Platt | Getty ImagesRite Aid filed for Chapter 11 bankruptcy protection in…
Novo Nordisk hikes outlook on hovering demand for Wegovy, Ozempic
Novo Nordisk on Friday raised its outlook for its full-year sales and operating profit due to soaring demand for its blockbuster weight loss drug Wegovy and…
Biden praises Kaiser Permanente settlement: ‘Collective bargaining works’
Healthcare workers strike in front of Kaiser Permanente Los Angeles Medical Center, as more than 75,000 Kaiser Permanente healthcare workers go on strike…
Pregnant Latinas face higher maternal well being issues
Zaza Cristina Robles worked as a pregnancy coach in her native Peru, so when she arrived in the U.S. at 16 weeks pregnant, the first thing she did after…
three Membership shares that Goldman Sachs assume will rally on earnings
It's encouraging to see three Club stocks on the bullish side of Goldman Sachs' new list of 25 tactical trades for earnings season. Asset allocation can be…
How Ozempic and Wegovy turned Novo Nordisk right into a $400 billion firm
Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy. The…
15 shares with dividend progress historical past anticipated to ship once more this yr
Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to…
Cramer says Vertex has a drug which will deal with the ‘largest market alternative on the…
CNBC's Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute…